Innovotech Inc. (TSX Venture Exchange:IOT; OTCQB:IOTCF) announced that its subsidiary, Innovotech Labs Corporation, is receiving advisory services and research and development funding of up to $234,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The funding will support the development of new antimicrobial testing services for medical devices such as catheters, implants, and wound dressings.
The new testing methods address changes in international regulatory standards and medical device manufacturers’ needs in the areas of proliferation, biofilm formation, and translocation of microorganisms. This work builds on foundational development initiated last year, advancing it into more robust, fit-for-purpose testing. As customer programs expand, manufacturers are requesting more advanced testing that better reflects real-world use and provides clearer decision-making data. Strengthening these capabilities will expand the Company’s service offerings, support regulatory readiness, and help customers demonstrate device safety and performance more effectively.
“This NRC IRAP support will help us to deepen our technical bench, problem solve for our customers and deliver solutions that reduce infections and complications for better health outcomes,” said Craig Milne, CEO. “It also positions us to meet rising client demand with higher-complexity testing and stronger technical support as standards and expectations continue to evolve.”
Innovotech is a leading life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. The Company is a recognized leader in biofilm science and antimicrobial testing and provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. Innovotech combines deep scientific expertise with proprietary methodologies and products, including its widely used MBEC Assay® platform for high‑throughput antimicrobial and antibiotic testing. Operating through ISO‑certified and GMP‑accredited laboratories, Innovotech supports clients across multiple sectors and geographies, delivering reliable, decision‑enabling data aligned with regulatory expectations such as those of the U.S. Food and Drug Administration and Health Canada. More information can be found at https://www.innovotech.ca.
The NRC IRAP support is expected to enhance Innovotech’s technical capabilities and expand its service portfolio, addressing the growing demand for sophisticated antimicrobial testing as regulatory standards become more stringent. This development is crucial for medical device manufacturers seeking to validate the safety and efficacy of their products, ultimately contributing to better patient outcomes by reducing infections and complications.
